Abstract:Recombinant adeno-associated virus (rAAV)-mediated liver transduction can induce transgene product-specific immune tolerance, which can be further extended to the systemic tolerance. Because of such tolerogenic properties and its physiological functions, the liver has been a preferred target organ for AAV- gene therapy. The hepatic regulatory T cells (Tregs) are regarded as the major factor that contributes the immune tolerance in the liver. Here, we first tested if AAV capsid plays a role in inducing systemic immune tolerance. To this end, we used highly immunogenic Ovalbumin (OVA) as a model antigen expressed under the direction of a strong ubiquitous chicken β-actin (CB) promoter and packaged the vector with both AAV1 and AAV8 capsids for in vivo delivery to C57BL/6 mice. Compared to AAV1, AAV8 achieved significantly higher OVA expression without IgG production, regardless of intravenous (IV) or intramuscular (IM) injection. In addition, IV and IM delivered AAV1. OVA both generated OVA-specific CD8+ T cells in spleen, while AAV8-mediated deliveries blunted CD8+ T cell response and, instead, provoked B- and T-Reg responses. In an attempt to explore other possible cellular mechanism(s) led to hepatic tolerogenic properties, we profiled expression of innate and adaptive immune responsive genes that are possibly associated with liver immune tolerance in the context of rAAV transduction. We revealed that rAAV1.CB. OVA injections significantly elevated IL1a and CXCL1 gene expression as compared to the PBS and rAAV8 groups. As rAAV8 is more liver tropic than rAAVl, we hypothesized that hepatic OVA expression is essential to inducing immune tolerance. We tested this hypothesis by creating rAAV8.CB. OVA vectors (+/-) the binding sites for the liver enriched miR-122 and IV dosing C57BL/6 mice with the vectors at 4 doses (1×109, 1010, 1011 and 1012 gcs/mouse). We confirmed that miR-122 indeed effectively inactivated OVA expression from rAAV8.CB. OVA(+)MiR-122BS transduced liver; however, rAAV8.CB. OVA(-) miR122BS but not rAAV1CBOVA achieved sustained OVA expression in a dose dependent manner without eliciting OVA specific IgG. Finally, considering that the route of rAAV administration may affect transgene expression and immunity, we IM injected C57BL/6 mice with AAV8.CB. OVA (+/-) miR122BS vectors and found that AAV8.CB. OVA (-)miR-122BS expressed OVA efficiently without OVA-specific IgG production. In contrast, just as rAAV1.CB. OVA did, rAAV8.CB. OVA(+) miR-122BS produced significant OVA-specific IgG without OVA expression. Interestingly, IM delivered rAAV8.CB. OVA(+) miR-122 group expressed significantly higher levels of CXCL1, Myeloperoxidase(Mpo) and CCL5 in liver, as compared the PBS and rAAV8OVA(-)miR-122 groups as detected by qRT-PCR. Our data suggest that the downregulation of CXCL1, Mpo, CCL5 and IL1α in the liver are involved in the immune tolerance to rAAV8 delivered transgene. Those cytokines may represent therapeutic targets against autoimmune diseases.

B cell focused transient immune suppression protocol for efficient AAV readministration to the liver

Repeated Systemic Dosing of Adeno-Associated Virus Vectors in Immunocompetent Mice After Blockade of T Cell Costimulatory Pathways

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction

Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy

457. Both Regulatory T and B Cells May Play Roles in Systemic Immune Tolerance Induced by Raav-Mediated Gene Transfer to Liver

Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer

Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74

Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver.

Double-stranded RNA Innate Immune Response Activation from Long-Term Adeno-Associated Virus Vector Transduction

Immune responses to AAV in clinical trials

Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I

Antibodies against the capsid induced after intracranial AAV administration limits second administration in a dose dependent manner

A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

Adeno-associated Virus (AAV) versus Immune Response

81. Downregulation of Immune Responsive Chemokines Are Associated AAV8-Mediated Transgene Immune Tolerance

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs.

Understanding AAV vector immunogenicity: from particle to patient

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors

The complex, confusing and poorly understood immune responses to AAV‐mediated gene transfer in haemophilia—Is more or less immunosuppression required?

The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy